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ReviewBioactive Compound Collections:
From Design to Target Identification
Luca Laraia,1,2,* Lucas Robke,1,3 and Herbert Waldmann1,3,*The Bigger Picture
The research summarized in this
review has implications for two of
the UN’s sustainable
development goals (SDGs). The
development of new and
improved strategies for obtaining
bioactive small molecules will
have a significant impact on good
health and well-being (UN SDG 3).
Because the development of a hit
compound to a drug typically fallsThe discovery of bioactive compounds underpins many areas of basic biomed-
ical research and constitutes a large part of medicinal chemistry and chemical
biology. Synthetic chemistry is now able to provide almost any drug-like mole-
cule imaginable. Therefore, attention has turned to increasing the biological
relevance of the compounds to be used in chemical biology andmedicinal chem-
istry research, as well as maximizing their diversity within this large area of
chemical space. In this review, we outline key concepts for the design of biolog-
ically relevant compound collections by taking inspiration from nature and
natural products. We highlight efficient ways to screen the resulting libraries
in order to maximize hit rates and the chance of discovering new modes of
action. Finally, we discuss state-of-the-art techniques for the identification of
molecular targets of hits identified through phenotypic screening approaches.in the remit of a pharmaceutical
company, the research also
contributes to industry,
innovation, and infrastructure (UN
SDG 9). All innovations that
increase the efficiency with which
the industry can bring a drug to
market are highly desirable.
One of the key messages of this
review is that compounds can
display a great degree of
biological diversity without having
significantly different structures.
As such, working with privileged
scaffolds, including natural
products, is a fruitful strategy for
discovering bioactive molecules.
In addition, knowing which assays
to use for assessing biological
diversity and maximizing the
chance of discovering bioactivity
is crucial.INTRODUCTION
The discovery of biologically active molecules to improve human health is among
the most important challenges in organic chemistry. Small molecules, which have
made up the bulk of therapeutic modalities over the last century, have been supple-
mented with biologics, including antibodies and nucleic acid derivatives, which
show great promise in the clinic. However, small molecules are and will continue
to remain excellent tools for the study of human health and disease, as well as poten-
tial therapeutics.
In the search for biologically active small molecules, a limiting factor has been the
availability of synthetic methods of accessing the necessary complexity required,
e.g., in the context of natural products (NPs). However, as a result of advances in
synthetic techniques, this challenge has largely been solved. With a broad and
well-developed chemical methods toolkit, the focus has increasingly shifted to
developing strategies for designing and identifying bioactive compound collec-
tions. Key questions in this area are which compounds should be synthesized and
what the most efficient ways to make them and assess their bioactivities are.
A good multi-purpose compound library will contain molecules that elicit diverse
phenotypes by modulating different targets, i.e., they display a great degree of di-
versity in bioactivity. Assessing biological diversity a priori is a challenging task. By
retrospectively analyzing the performance in high-throughput screening (HTS), re-
searchers at Novartis developed ametric termed HTS fingerprint (HTS-FP), which as-
sessed a compound’s activity in over 190 HTS campaigns over a period of 10 years.1
It was found that a compound set with a high degree of diversity in HTS-FP was pre-
dictive of further biological diversity in subsequent screens. In addition, compounds
with a high degree of similarity in their HTS-FP were also significantly more likely to
act via a similar mode of action.2 This is particularly crucial for NPs, which are oftenChem 4, 705–730, April 12, 2018 ª 2018 Elsevier Inc. 705
poorly covered by chemical descriptors. A key conclusion of their work was that that
biological diversity did not necessarily originate from chemical diversity.
In this review, we focus on the design, synthesis, and evaluation of biologically active
compound libraries. A variety of strategies for accessing biologically relevant and
diverse areas of chemical and biological space are described. Phenotypic screening
strategies for maximizing the likelihood of identifying a compound’s bioactivity and
cell-based techniques for rapid assessment of biological diversity are covered.
Finally, state-of-the-art techniques for addressing the inevitable target-identifica-
tion challenges that are associated with the phenotypic approach are discussed.1Max Planck Institute of Molecular Physiology,
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NPs have been, and continue to be, excellent sources of bioactive compounds and
clinically used drugs.3,4 In addition to using the NPs themselves, simple derivatiza-
tion reactions can also access analogs with improved potency and biophysical
properties. Twenty-eight percent of all currently approved drugs are either NPs
or derivatives thereof.5 NPs have evolved over time to carry out specific functions
for the organisms that produce them.6 They are particularly effective agents for de-
fense and signaling purposes, and as such, often regulate key cellular pathways.7
In addition, as a result of their biosynthetic pathways and associated feedback
mechanisms, NPs and their precursors are able to interact with a range of enzymes.
Crucially, NPs are typically not promiscuous, but small variations in their scaffolds
and substituents allow them to engage different biomolecular targets with high
specificity.8,9
Disadvantages are that NPs are often only present in low amounts from their natural
sources, and they may not contain suitable reactive sites for further elaboration and
determination of structure-activity relationships. However, advances in synthetic
chemistry and total synthesis in particular have enabled the scale-up of NP synthetic
routes. A particularly impressive example is the synthesis of eribulin (Halaven), a clin-
ically approved anti-mitotic that is derived from the NP halichondrin B.10 An inter-
esting deviation from traditional total synthesis is diverted total synthesis. In this
approach, the retrosynthetic strategy is planned so that a late intermediate can be
diversely functionalized to access a variety of analogs.11
Despite the complexities in their synthesis and derivatization, NPs have had a resur-
gence in recent years. This is partly due to several analyses that showed that an in-
crease in the fraction of sp3 carbons (Fsp3) and stereogenic centers correlated well
with future success in clinical trials.12 NPs have a high Fsp3, typically around 0.68,
which is significantly higher than the average commercially available compound
collection often used in typical large screening campaigns, which has an Fsp3 of
around 0.37.13 Although flat molecules have been developed into valuable drugs,
there is a demand for more structural diversity and complexity in the design and as-
sembly of small-molecule libraries.14 Motivated by the success of NPs, those that are
commercially available in large quantities have been derivatized.15,16 In addition to
simple derivatizations, changes to the core scaffolds of NPs can also lead to
increased scaffold diversity and bioactivity. In a recent report, Garcia et al.17 started
from a single NP to obtain a library consisting of 16 different scaffolds. This was
achieved by transforming the alkaloid sinomenine by ring distortion reactions (Fig-
ure 1). Ring fusion, expansion, cleavage, contraction, (de)aromatization, and rear-
rangement reactions of the four fused rings of sinomenine generated a library of
65 compounds.706 Chem 4, 705–730, April 12, 2018
OMe
OH
O
OMe
N
H
OMe
OH
N
H
OMe
OH
OMe
N
H
O
NH
O
O
6
Ring Fusion
Ring Expansion
OMe
H O
2
Ring Fusion
Ring Cleavage
N
NN
N
O
H
3
Ring Fusion
Ring Contraction
NH
MeO O
N3 O
O
4
Ring Fusion
Ring Expansion
OMe
OMe
N
5
Ring Rearrangement
Ring Aromatization
1
Sinomenine
spets4spets4
5 steps
4 steps
4 steps
Figure 1. Selected Examples of a Sinomenine-Derived Compound Library
Through ring distortion reactions, the alkaloid NP sinomenine was transformed into diverse
scaffolds.17Sinomenine (1) is a particularly suitable candidate for the ring distortion and modi-
fication of NPs strategy, as it is structurally complex (containing three stereogenic
centers and four fused rings) and contains several functional groups that allow
further chemical modification. Sinomenine itself has immunosuppressive and anti-
inflammatory activities.18 In this regard, it will be interesting to see what biological
activity sinomenine’s analogs will present.
The cinchona alkaloids display a broad bioactivity profile, which ranges from the
antimalarial quinine to the antiarrhythmic quinidine (Figure 2A, 7 and 8).19 They
are also excellent substrates for the synthesis of compound collections because
they contain several orthogonal functional groups for diverse functionalizations.
To that effect, a library based on quinine was reported by Hergenrother and co-
workers as part of a larger effort to deploy their ring distortion and modification
strategy.20 The cinchona alkaloids quinidine (8b) and cinchonine (8a) can be cyclizedChem 4, 705–730, April 12, 2018 707
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Figure 2. Cinchona-Alkaloid-Derived Compound Libraries
Cinchona alkaloids (A) and the synthesis of an oxazatwistane-derived compound collection (B).in acidic conditions to yield the highly strained oxazatricyclo[4.4.0.0]decane (oxazat-
wistane, 9) scaffold.21 It was proposed that the key variation in the scaffold as a result
of the cyclization may also endow these compounds with a different bioactivity pro-
file. Therefore, a library of oxazatwistane-derived compounds, with modifications
around the quinoline core, was synthesized with C–H functionalization reactions
and metal-catalyzed cross couplings (Figure 2B).22
Overall, a library of 47 compoundswas synthesizedand subsequently tested ina rangeof
phenotypicassays. Thisenabled the identificationof severalpotentautophagy inhibitors,
which were characterized further to reveal an unusual mode of action. Crucially, none of
the parent NPs (7 and 8) showed any autophagy inhibitory activity under the screening
conditions, and thus the oxazatwistane moiety was essential for activity. Thus, using
NPs as starting points for library synthesis and modifying their core scaffolds as well as708 Chem 4, 705–730, April 12, 2018
their substitution patterns remains a viable strategy for identifying biologically active
compounds with interesting modes of action.BIOLOGY-ORIENTED SYNTHESIS
Although NPs have provided a wealth of drugs, their often challenging synthesis
and modification limit their application in modern drug discovery. Biology-ori-
ented synthesis (BIOS) addresses this limitation by guiding the structural simplifi-
cation of NPs, in order to ease synthesis, while maintaining their biological
relevance.9,23 BIOS aims to access NP-inspired compound collections without
necessarily synthesizing the NP itself. The underlying assumption behind the
approach is that if the core scaffold found in the NP is retained in the library,
then a substantial portion of the bioactivity should be retained as well. In this
context, a scaffold is defined as the combination of ring systems and the linkers
that bring them together.6 To classify NPs on the basis of their constituent scaf-
folds, the structural classification of NPs (SCONP) was devised.24 For NPs, the
largest scaffold (‘‘child’’) was deconstructed one ring at a time to deliver the
‘‘parent’’ scaffolds until only one ring system remained. The combination of all
scaffolds and their constituent ring systems forms the so-called NP tree (Figure 3).
This was subsequently expanded to include non-NPs as well, making it a useful
tool for classifying compound collections more generally. The accompanying soft-
ware to carry out the analysis is freely available at https://sourceforge.net/projects/
scaffoldhunter/files/.25
The NP scaffold tree can be used to selected parent and child scaffolds around which
to base compound libraries, which can be particularly efficacious when the accom-
panying bioactivity data are included. Focusing libraries on the scaffolds not
explored previously may cover new intellectual property space in addition to deliv-
ering new bioactive compounds.
The BIOS principle was successfully applied to the withanolide class of NPs by
Svenda et al.26 The withanolides, a steroid-containing class of NPs comprising
more than 300 members, exhibit various bioactivities.27–30 A library of small
molecules containing a trans-hydrindane dehydro-d-lactone scaffold, which is
characteristic of withanolides, was designed and synthesized via the preparation
and selective functionalization of three key intermediates (Figure 4A, 12–14).
Those key intermediates were then further derivatized by a maximum of two
steps leading to final compounds of type 15–17. Subsequent biological investi-
gations identified compounds of type 18 to be inhibitors of the developmental
Hedgehog pathway by blocking the function of the smoothened protein
(Figure 4B).
Further supporting the versatility of the BIOS principle, another withanolide-inspired
and pregnenolone-derived d-lactone-based compound collection was recently
reported to deliver inhibitors of the Wnt pathway (Figure 4B).31FUSION OF NATURAL PRODUCT FRAGMENTS
NPs are promising starting points for the development of compound collections with
biological relevance. Therefore, as an extension of the BIOS principle, the fusion of
different NP scaffolds offers the possibility to generate compound libraries that
consist of multiple biologically pre-validated substructures and should thus lead
to an enrichment of potential biological activity.32 A chemoinformatic analysis of
180,000 NPs led to 2,000 fragments, which are diverse, rich in sp3-configuredChem 4, 705–730, April 12, 2018 709
Figure 3. The NP Scaffold Tree
Reproduced from Koch et al.24 Copyright 2005 National Academy of Sciences.carbons, and similar in their properties to NPs themselves. Their coverage of chem-
ical space is very different from commercially available compound libraries, thus of-
fering more starting points for the identification of novel chemotypes.33
One such NP fragment is the bicycle tropane. Tropanes can be found in over 600
naturally occurring alkaloids and several of those are used in medical applications,
such as the treatment of neurological or psychiatric impairments.34,35 However,
the complex structure of tropanes poses a challenge for an efficient enantioselective
synthesis. A suitable synthetic method has been developed by Narayan et al.36 by
means of a CuI-catalyzed [3 + 2] cycloaddition of 1,3-fused cyclic azomethine ylides
20 and nitroalkenes 21 (Figure 5A). In this approach, the 1-3-fused ylide reacts as the
dipole with the nitroalkene as a comparably low-reactivity dipolarophile to form two
new bonds and five stereocenters.
This one-step reaction allowed the generation of a library containing 84 tropane-based
compounds. Of the compounds obtained, analogs consisting of an indole-tropane710 Chem 4, 705–730, April 12, 2018
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smoothened and thus an inhibitor of Hedgehog signaling. The sterol-derived compound 19 was found to be an inhibitor of Wnt signaling.31scaffold are particularly noteworthy because these NP fusions represent an unprece-
dented class of hedgehog (Hh) pathway inhibitors (24 and 25; Figure 5B).
Another combination of NP fragments was achieved by uniting tropanes and pyrro-
lidines through a diastereo- and enantioselective cycloaddition reaction. Starting
from the racemic tropane 26, only one enantiomer reacted under dynamic kineticChem 4, 705–730, April 12, 2018 711
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Figure 5. Synthesis and Biological Activity of Indotropanes
(A) Schematic representation of the one-step reaction for the generation of a tropane-based
compound library.
(B) Indole-tropane fusion products were found to be novel chemotypes for the inhibition of the
Hedgehog (Hh) pathway.resolution conditions (Figures 6 and 7).37 In a first approach, the 1,3-dipolar cycload-
dition of the racemic tropane rac-26 as a dipolarophile with the dipole 27 was estab-
lished with a copper catalyst and a phosphine ligand 28 (Figure 6). This delivered the
desired product 29 as well as the starting material in excellent enantiomeric excess.
Subsequently, enantiodivergent access to both possible absolute configurations of
the products 32 and 34 was developed by subjecting the racemic tropane 30 to
two different ylides in a sequential manner (Figure 7). In a one-pot reaction, two
products with opposing absolute configurations were obtained with only one chiral
ligand.
DIVERSITY-ORIENTED SYNTHESIS
A different but related strategy for the design and generation of a diverse library of
small molecules, which is not typically based on NPs, is diversity-oriented synthesis
(DOS). This strategy has emerged as a powerful approach for generating unbiased
screening compounds.38 The key difference to NP-derived and inspired libraries,
such as those synthesized by BIOS, is that the key driver is the attainment of com-
pounds that are as chemically diverse as possible. Chemical diversity is typically
assessed by cheminformatic analysis, where new libraries are compared with
representative sets of NPs (high chemical diversity) and non-NP drugs (low chemical
diversity).39 Low indicators of similarity indicate a diverse compound collection. The
general hypothesis in this approach is that a large coverage of chemical space will
also result in a broader coverage of biological space. Several strategies for accessing
diverse compound libraries by DOS have been reported. In the reagent-based
approach, a polyfunctional startingmaterial is typically converted to a range of prod-
ucts by simply varying the reaction conditions (Figure 8A).40 In the substrate-based
approach, a diverse array of substrates is subjected to the same reaction conditions
to access diverse molecular frameworks (Figure 8B). To achieve a high degree of
chemical diversity, one typically has to access molecules that contain diverse scaf-
folds. Thus, simply functionalizing one scaffold at different reactive sites would not
deliver a library that is characterized by a high degree of chemical diversity.
Frequently in combinatorial chemistry, very large libraries consisting of very few scaf-
folds were prepared, which resulted in low hit rates and low biological relevance. Un-
doubtedly, DOS holds great promise for bioactive compound discovery, but the712 Chem 4, 705–730, April 12, 2018
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Fragmentschoice and identification of chemical structures that also possess biological activity
in a completely unbiased manner remain a challenge.
In an attempt to increase the biological diversity and relevance of libraries prepared
by DOS, several variations of this approach, such as incorporating NP scaffolds,41
have been developed. Similarly, another DOS-based approach involves the inclu-
sion of so-called privileged scaffolds or substructures (pDOS) beyond those found
in NPs.42 In a recent report using a substrate-based pDOS, Kim et al.43 employed
a group-pairing strategy of five reactive sites on pyrimidodiazepines 35 (Figure 9).
With an average of 2.2 steps, 16 distinct polyheterocycles were prepared, contain-
ing pyrimidines and/or diazepines. Both of these are known to possess various bio-
logical activities.44–46 As a proof of concept, an ELISA-based HTS assay for inhibitors
of the protein-protein interaction of leucyl-tRNA synthetase (LRS) and Ras-related
GTP-binding protein D (RagD) was used. A compound that specifically inhibited
the LRS-RagD interaction was identified, which allowed the regulation of the activa-
tion of the mechanistic target of rapamycin (mTORC1).
LIGAND-DIRECTED SYNTHESIS
In most cases, the generation of compound libraries is a laborious endeavor,
because the transformation of starting materials is performed in a step-by-step
manner in independent experiments, in order to achieve structural diversity. For
this reason, new approaches that diversify starting materials in a more unified way
would offer great value.47–49 In this regard, Lee et al.50 developed a synthetic strat-
egy that utilizes different ligands in AuI catalysis to transform oxindole-based
1,6-enynes to selectively synthesize spirooxindoles, quinolones, or df-oxindoles
(Figure 10).
The key to this strategy was to identify reactions, which proceed through a common
intermediate, whose reaction path can be influenced by different ligands. Therefore,
this approach was termed ligand-directed synthesis. Adjusting the ligand’s proper-
ties, including steric and electronic demand, and fine-tuning the reaction conditions
for each transformation could steer the common intermediate’s fate down different
reaction paths (Figure 11). In the presence of the most electrophilic complex I, cyclo-
propane ring migration 50 or formation of a benzylic carbocation 51 might be
favored, leading to spirooxindole 45. In contrast, the most bulky ligand, which is
also the least electrophilic, is proposed to lead to an oxonium-quinolone gold inter-
mediate 52 by relieving the strain at intermediate 49. The compromise in steric hin-
drance and electrophilicity, catalyst II, allows nucleophilic attack by methanol, which
opens the cyclopropane ring, eventually yielding compound 47.Chem 4, 705–730, April 12, 2018 713
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Only one chiral ligand was used to generate two different enantiomers from racemic tropane 30.The diverse compound library generated contained compounds that were selective
inhibitors of Wnt signaling, Hedgehog signaling, autophagy, or cellular prolifera-
tion. Interestingly, these activities depended on the scaffold structure. This finding714 Chem 4, 705–730, April 12, 2018
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Adapted by permission from Springer Customer Service Centre GmbH: Springer Nature, Nature
Communications, Galloway et al.,40 copyright 2010.proves the applicability and versatility of ligand-directed synthesis for the genera-
tion of compound libraries with privileged scaffolds showing high potential to
exhibit biologically active substances.
In addition to gold, other metals have the ability to catalyze diverse processes to
obtain various scaffolds from the same starting material, including palladium.48 An
interesting example of its use to steer reactivity in two opposing directions to yield
different products was reported by Alza et al.51 Starting from the oxidative insertion
of palladium into multifunctional intermediate 56, two possible reaction pathways
were observed. Transmetalation with boronic acids led to the direct Suzuki product
59,52 whereas a syn-migratory insertion followed by transmetalation led to a 6-5-5-6
fused-ring system (62) by a domino Heck-Suzuki-type process (Figure 12).
Varying the palladium source and the ligand enabled the selective synthesis of each
scaffold. After screening for anti-mitotic activity, both compounds were found
to impair the division of U2OS osteosarcoma cells by different mechanisms.54
Whereas the most potent direct Suzuki product (dosabulin, 63) inhibited tubulin
polymerization, the domino Heck-Suzuki product 64 caused chromosome congres-
sion defects without affecting tubulin polymerization. It would be interesting to
determine the molecular target of this molecule, which is currently unknown.
IDENTIFYING BIOLOGICALLY ACTIVE MOLECULES
Screening a large (>100,000) compound library in a target-based assay typically
yields a satisfactory number of hits to pursue. However, focused compound libraries
(<1,000 compounds) such as NP-inspired collections, may better be explored by
screens that cover broad areas of biological space, where multiple targets are rep-
resented, to enable the identification of bioactive compounds. Unbiased pheno-
typic screening offers this possibility because different potential targets may be
associated with a given phenotype.53 In addition, hits identified by phenotypic
screening are cell permeable by definition and may act by a polypharmacological
mechanism, which may be desirable for particular therapeutic applications, e.g., in
certain neurological diseases and cancer.54
Image-based screens are particularly valuable because they allow the assessment of
cellular morphology and viability in addition to the phenotype of interest. Typical
screens involve the use of fluorescently tagged proteins or fluorescent antibodies
to a specific protein to image key processes in the cell. Advances in automatedChem 4, 705–730, April 12, 2018 715
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The group-pairing strategy led to compounds containing privileged substructures, one of which
inhibited the interaction between LRS and RagD.image acquisition and analysis have made screening of large libraries in this format
practical. Early examples included the identification of new anti-mitotics.55 Mitosis
can be visualized easily by microscopy because of the large structural rearrange-
ments in a cell during this process. In addition, a wealth of markers for the different
mitotic phases exist and have been successfully used. The phosphorylation of his-
tone H3 is a prometaphase marker that is routinely employed to identify cells ar-
rested at this point, after compound treatment. The anti-mitotic activity of dosabulin
and HS-1 was identified by this approach (Figure 12).51,52
Another phenotype that can be successfully studied by image-based screening is
autophagy. Autophagy is a conserved cellular mechanism for the degradation and
recycling of cellular waste material as well as pathogens and is upregulated
in situations of stress, such as nutrient deprivation (Figure 13A).56 Autophagy inhibi-
tion has been proposed as a potential anti-cancer strategy because it may promote
tumor survival and growth.57 For identifying autophagy inhibitors by phenotypic
screening, a cell line stably expressing a GFP-tagged variant of the protein microtu-
bule associated light chain 3 (LC3) can be used, which enables the visualization of
autophagosomes in live and fixed cells (Figure 13B). Upon autophagy induction,
LC3 localizes to autophagosomes, which can be quantified by image analysis716 Chem 4, 705–730, April 12, 2018
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cinchona alkaloid derivative that acts via a dual mode of action,22 a coumarin
with an as yet unknown target,58 and a deubiquitinase inhibitor were identified
(Figure 13C).59
In addition to screening for a specific phenotype, multiparameter imaging or
profiling can be used to assess biological activity and diversity in a very general
sense and to identify potential targets by similarity to known reference com-
pounds.60,61 In ‘‘cell painting,’’ five or six different dyes are used to stain different
cellular compartments.62 After compound treatment, thousands of parameters are
calculated to create a cellular profile or fingerprint for each compound.63 This is
compared with the profiles of a large (ideally >5,000) set of reference compounds
of known bioactivity and with known targets. Therefore, for every new compound
tested, one can determine whether (1) the compound affects the parameters
measured and (2) the fingerprint it produces is similar to any reference compound.
The comparison with a reference set is particularly useful because it can give an early
indication of a mode of action. Even if a compound does not perturb cellular
morphology, it may still be biologically active. In fact, a large number of reference
compounds show no visible effect in the cell-painting assay. A particularly inter-
esting application of the cell-painting assay has been to determine the biological di-
versity of a compound collection.64 A high degree of diversity in fingerprints in the
cell-painting assay was found to be predictive of diversity in future cell-based pheno-
typic screens, regardless of the phenotype measured. A strategy similar to pheno-
typic analysis, known as morphobase, which focuses on changes in cellular
morphology by using bright-field microscopy images, nuclear morphology, and a
nuclear dye, has been reported.65
In addition to image-based screening methods, gene-reporter and viability assays
are frequently used. For example, gene-reporter assays are used to identify inhibi-
tors of developmental signaling pathways with relevance to cancer, such as Hedge-
hog (Hh), Wnt, and Notch. The clinically used Hh signaling inhibitor vismodegib was
identified by this approach and has become a poster child for the technique.66 With
this approach, inhibitors of both Wnt and Hh signaling from NP-inspired compound
collections were identified (Figures 4B, 5B, and 10).
TARGET IDENTIFICATION
One of the major bottlenecks in phenotypic screening is the identification of the
molecular targets of bioactive compounds.67 The difficulty of this step depends
on a range of variables, which include the novelty of the chemical structure and
the cellular localization and abundance of its target. If a compound’s structure isChem 4, 705–730, April 12, 2018 717
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Figure 11. Mechanistic Pathway of the Ligand-Directed Synthesis of Spirooxindoles 45, Quinolones 46, and df-Oxindoles 47
The common intermediate was formed by 6-endo-dig cyclization and cyclopropane formation starting from O-crotonylated substrate 44. Depending
on the ligand and the reaction conditions, the fate of the intermediate 49 was decided. The most electrophilic AuI catalyst (I) led to spirooxindole 45
(orange reaction path). Quinolones 46 were formed in the presence of the quite bulky gold complex III (blue reaction path). The less bulky and less
electrophilic gold complex II led to the df-oxindoles 47 (green reaction path). Adapted from Lee et al.50similar to other bioactive molecules with known targets, this provides a good
starting point for target ID. Assessing similarity to known bioactive molecules forms
the basis of most computational target prediction tools, including freely available
programs (Table 1). These operate by using a range of algorithms to compare
the 2D and predicted 3D structures of ligands with those found in databases
such as Chembl. The similarity ensemble approach (SEA) compares proteins by
the set-wise chemical similarity of their ligands.68 Swiss target prediction and
SuperPred use a combination of 2D and 3D similarity measures to compare a
new ligand with known ligands of many thousands of putative targets.69,70
ChemProt offers similar target prediction tools, but also enables the user to search
by target or even disease type.71 The self-organizing map-based prediction of drug718 Chem 4, 705–730, April 12, 2018
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(A) Catalytic cycle for the synthesis of the diverse scaffolds.
(B) Selected compounds with anti-mitotic activity.equivalence relationships (SPiDER) method uses self-organizing maps (SOMs) to
relate a query compound to known bioactive substances according to chemical
similarity features, such as pharmacophore features and physical and chemical
properties.72 It may be beneficial to use multiple computational target prediction
tools and subsequently select putative targets for validation that are found in
several of the approaches used. With SPiDER, it was recently possible to identify
the target of the Hedgehog signaling inhibitor Smoothib as the G-protein-coupled
receptor (GPCR) Smo.73Chem 4, 705–730, April 12, 2018 719
Figure 13. Identification of Autophagy Inhibitors by Phenotypic Screening
(A) Schematic of the autophagic process.
(B) Autophagy was induced by amino acid starvation in MCF7 cells stably transfected with eGFP-LC3. Autophagosomes can be viewed as green puncta
or spots, and nuclei are shown in blue. Accumulation of LC3 puncta can be reversed by autophagy inhibitors. Scale bar: 110 mM.
(C) Autophagy inhibitors identified by phenotypic screening.22,37,45Computational tools can work very well when the target falls within the limited num-
ber that already have a known ligand. These include kinases and GPCRs, which make
up a disproportionate number of targets for known drugs. The non-systematic
analog of computational target prediction can be described as an educated guess.
For example, it may be possible to predict kinase inhibition by visual inspection of
the hit molecule, because many kinase inhibitors contain motifs that enable binding
to the conserved hinge region of the proteins. For instance, this approach was used
to identify the targets of epiblastin, a triamterene-derived pteridine (68) that was
found to act by inhibiting Casein Kinase 1 (CK1d), and a neuritogenic militarone-
derived 4-hydroxypyridone (69) that was found to target MAP4K4 (Figure 14).76,77
For individual target classes, target prediction may be validated experimentally by
means of assays available from commercial suppliers. For instance, various kinase720 Chem 4, 705–730, April 12, 2018
Table 1. Free and Proprietary Computational Target ID Tools
Software Producer Web Address
Similarity Ensemble
Approach (SEA)
Kaiser and Shoichet
labs68
http://sea.bkslab.org/
Swiss Target
Prediction
Michelien lab69 http://www.swisstargetprediction.ch/
ChemProt Technical University
of Denmark and Universite´
Paris Diderot71
http://potentia.cbs.dtu.dk/
ChemProt/
SuperPred Structural Bioinformatics
Group, Charite´70
http://prediction.charite.de/
Target Hunter Xie lab74 http://www.cbligand.org/
TargetHunter/
Chemical Similarity
Network Analysis
Pull-down (CSNAP)
Torres lab75 http://services.mbi.ucla.edu/
CSNAP/
Self-organizing-map-
based prediction of
drug equivalence
relationships (SPiDER)
Schneider lab72 http://modlabcadd.ethz.ch/
software/spider/panels can be accessed at reasonable cost from companies including Life Technologies
and Cerep. In addition, GPCR assays are also available at Cerep and DiscoveRx. How-
ever, testing selectivity against a panel of GPCRs is still prohibitively expensive for most
labs. Roth and coworkers recently developed a tool that enables high-throughput
testing against over 300 non-olfactory GPCRs in parallel. The parallel receptorome
expression and screening via transcriptional output, whereby transcriptional activation
follows an arrestin translocation (PRESTO-Tango) approach, has been made available
from Addgene at an affordable cost (Figure 15).78,79
This approach uses a construct consisting of the GPCR of interest joined to the tran-
scriptional activator (tTA), which contains a TEV protease cleavage site in between.
A second construct consisting of the TEV protease linked to human arrestin-2 is
transfected simultaneously in a cell line that contains a tTA-dependent reporter
gene. Activation of a GPCR results in b-arrestin recruitment, proteolytic cleavage
by the linked TEV protease, and freeing of tTA to enter the nucleus and activate re-
porter genes. Because the association of b-arrestin with ligand-bound receptors is
observed for most GPCRs, it was possible to expand this system to a very large
portion of all GPCRs. The assay was amenable to a multi-well plate format, and ro-
botics made it possible to screen for agonist activity against almost all non-olfactory
GPCRs. The assay format can also be run in antagonist mode for GPRCs with known
agonists. The PRESTO-Tango system will facilitate target ID when GPCRs are puta-
tive targets and enable testing for compound selectivity across the GPCRome.
When educated guesses and computational target predictions are unsuccessful, the
go-to methods are typically mass spectrometry (MS)-based proteomic approaches.
The corresponding typical affinity-isolation experiment (‘‘pull-down’’) involves the
synthesis of a suitably functionalized derivative of a hit compound, which can be im-
mobilized onto solid phase and incubated with cell lysates to capture bound pro-
teins non-covalently. Advances in mass spectrometers and analysis tools have
made such methods very sensitive, and the use of stable isotope labeling with amino
acids in cell culture (SILAC) enables quantification of individual peptide signals
and increases the confidence in the hits obtained.80 Progress in these and
similar proteomic experiments has been reviewed extensively and is thus not
covered here.67,81,82 A major drawback of the typical pull-down experiment is theChem 4, 705–730, April 12, 2018 721
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See Ursu et al.76 and Schro¨der et al.77requirement of using cell lysates rather than intact cells, which leads to the exclusion
of many, if not all, membrane proteins, including the aforementioned GPCRs. To
circumvent this issue, bifunctional probes containing a photoreactive functional
group, such as a diazirine, an aryl azide, or a benzophenone, as well as a bio-
orthogonal handle for further functionalization to aid subsequent detection or isola-
tion, can be used (Figure 16).83
The addition of small functional groups such as diazirines or alkynes is often toler-
ated biologically and enables the probe to be administered to live cells, where it
can bind targets in their native environment, including membranes (Figure 17). After
irradiation to release the reactive intermediate, the probe binds its target covalently.
Subsequently, it can be coupled via, e.g., a copper or strain-promoted click reaction
to a linker coupled to a fluorophore for in-gel visualization or a biotin group for isola-
tion. As the target is covalently bound, more stringent washing to remove proteins
that bind non-specifically to the solid phase is possible. This approach is also
amenable to SILAC, providing a robust setup for identifying a wide range of poten-
tial targets. In addition to a direct MS readout, a method termed fluorescence differ-
ence in two-dimensional gel electrophoresis (FITGE) uses differential labeling of
positive and negative bifunctional probes with Cy3 and Cy5 dyes.84 A 2D gel sepa-
rates all proteins by size and pH, and those that are enriched in the positive bifunc-
tional probe can be excised and analyzed.
A recent application of this technique by the Cravatt lab has pushed this technology
to the limit of what is currently feasible.85 By coupling a bifunctional handle contain-
ing a diazirine and an alkyne to a small fragment collection, they were able to identify
target proteins of 14 basic fragments in an unbiased cell-based profiling. By
increasing the number of fragments to 465 and slightly increasing their complexity
and molecular weight (to an average of 340 Da), a phenotypic screening set was es-
tablished. This contained matched pairs of probes with and without the bifunctional
handle. From a subset of the elaborated fragment library containing 300 com-
pounds, three were able to induce differentiation of preadipocytes to adipocytes
at 50 mM, including compound 70 (Figure 18). With the corresponding bifunctional
probe 71 and chemical proteomics, the target was identified as progesterone recep-
tor membrane component 2 (PGRMC2). Compound 70 was subsequently character-
ized as a positive regulator of PGRMC2, and the role of this protein in adipogenesis
was validated further by genetic methods.
One of the disadvantages of the proteomic strategies outlined is the requirement
for the synthesis of a suitably functionalized pull-down probe. To circumvent this722 Chem 4, 705–730, April 12, 2018
Figure 15. The PRESTO-Tango GPCR Profiling Platform
The design of the construct is shown on top, and the assay format is depicted below. Upon ligand
binding (1), the b-arrestin-TEV protease fusion protein is recruited to the GPCR (2) and cleaves off
the tTA group. This is then free to translocate to the nucleus (3) and activate the tTA reporter gene
(4), which eventually gives rise to a luminescent signal.78problem, thermal proteome profiling (TPP) was developed (Figure 19).86 Originally
intended as a target validation strategy for showing target engagement in cell
lysates, it is now increasingly being used in the target ID process.87 Cell lysates
are heated to different temperatures in the presence or the absence of a hit com-
pound, and after digestion and labeling with up to 11 isotopically different labels,
known as tandem mass tags (TMTs), samples are recombined and analyzed by MS.
This enables the determination of melting curves across the whole proteome (mel-
tome). Proteins that are significantly stabilized or destabilized by a hit compound
are classed as putative targets. TMT labeling is becoming more common for a
range of proteomic applications beyond target identification because of the ability
to multiplex a large amount of different samples or treatment conditions.88 Similar
results can also be achieved with the isobaric tag for relative and absolute quan-
tification (i-TRAQ). Disadvantages of the TPP approach include the fact that the
stability of some proteins is not significantly altered by compound binding and
that this type of experiment typically yields a large list of putative hits, increasing
the challenges of target validation.
A variation of this approach that does not require TMT labels is the thermal-stability-
shift-based fluorescence difference in two-dimensional gel electrophoresis (TS-
FITGE).89 In this approach, DMSO- or compound-treated samples heated to the
same temperature are centrifuged, differentially labeled with Cy3 and Cy5 dyes,
and recombined. A 2D gel separating proteins according to size and charge is run
for each temperature, and differences in fluorescence intensity are quantified. In
this way, a melting curve for each spot can be generated, and those that show dif-
ferences between compound treatment and DMSO can be excised and analyzed
by MS. This approach identified the targets of the complex NP bryostatin.
A target ID strategy that works by measuring changes in protein levels on a prote-
ome-wide scale is chemproteobase.90 In this approach, cells are treated with a hit
compound in parallel to a DMSO control. After cell lysis, samples are labeled with
two different fluorophores and then recombined. Proteins are separated on a 2D
gel, enabling the visualization of changes in fluorescence between the DMSO controlChem 4, 705–730, April 12, 2018 723
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Figure 16. Photoreactive Functional Groups and Biorthogonal Handles for Isolation or Labelingand the compound-treated samples. Automated image analysis is used to compare
the profile of cells treated with a hit compound with a reference set of compounds
with known bioactivities. This allows the user to predict whether the compound
acts via a similar mechanism of action to a reference compound. This approach was
used to identify the target of theNPpyrrolizilactone as theproteasomeand the target
of the autophagy inhibitor autophinib as the lipid kinase VPS34.45,91
In addition to chemical, computational, and proteomic methods for target identifi-
cation, genetic methods have been used as potential strategies for identifying tar-
gets for bioactive small molecules. Several strategies have relied on yeast as a
simplified model organism for target ID. Haploinsufficiency profiling (HIP) relies on
the deletion of one allele of each gene in the yeast genome. For the target of a small
molecule, this should result in increased sensitivity to the compound. Homozygous
profiling (HOP) involves the deletion of both alleles of a given gene. Although this
does not directly identify a target, it can provide information on the network of inter-
acting genes. Both approaches (HIP and HOP) are often combined for increased in-
formation on putative targets and their network connectivity. As these strategies
have been the focus of extensive reviews, they are not discussed further in this
work.92 One key disadvantage of yeast-based target ID approaches is that yeast ge-
netics can differ significantly from human genetics, and as such, one could miss a po-
tential target when profiling compounds in yeast. Therefore, in recent years, an
increased focus has been placed on identifying new genetic approaches for target
ID that can be carried out in mammalian cells.93
An important step forward was the discovery of a near-haploid chronic myelogenous
leukemia cell line termed KBM-7.94 This has given rise to haploid genetic screening
platforms that can be used for target IDmethods.95,96 By heavily mutagenizing these724 Chem 4, 705–730, April 12, 2018
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A bifunctional probe is incubated with cells and irradiated to generate the reactive carbene. This reacts specifically with proximal target proteins. After
click chemistry with a functional handle, e.g., biotin, bound proteins can be enriched on a streptavidin-coated solid phase. After proteolytic digest on
the retained proteins, these can be analyzed by their constituent peptides via MS.cells, mutations in every potential gene are present in a large population. Com-
pounds with unknown modes of action that are also cytotoxic are tested in this
cell line at a lethal concentration. Colonies that are able to grow in these conditions
are sequenced and analyzed for mutations. Mutations can occur in the target pro-
tein; however, they may also occur in transfer proteins necessary for the uptake of
themolecules or metabolic enzymes that render the small molecule inactive.97 A lim-
itation of this technique is that it requires a toxic molecule for resistant colonies to be
generated; however, if this prerequisite is satisfied, it is a valuable addition to the
target ID toolkit.
A similar approach for the target ID of cytotoxic compounds is the use of the Cancer
Cell Line Encyclopedia (CCLE).98 This resource contains 947 human cancer cell lines,
which have been subjected to gene expression profiling, chromosomal copy number
analysis, and massively parallel sequencing. This was initially assembled to predict
which tumor types were most likely to respond to specific treatments. However,
the strategy was recently adapted for target ID purposes. The NP englerin A was
tested in 524 cell lines from the CCLE and was found to only be toxic in a specific
subset.99 This correlated strongly with mRNA levels of the short transient receptor
potential channel 4 (TRPC4). As siRNA knockdown of TRPC4 did not correlate with
compound activity, it was speculated that the compound may act as an agonist
rather than an antagonist of this calcium channel. This target hypothesis was inde-
pendently validated by two research groups.99,100OUTLOOK
Although great advances have been made in the design and synthesis of bioactive
compound collections, as well as their biological evaluation, significant challenges
still remain, which are currently being addressed to different degrees. Given the
vast amount of possibilities, the selection of scaffolds on which to base compound
collections remains a key discussion point and challenge. Interestingly, since the
introduction of DOS, BIOS, and variations thereof, very few new principles for the
design of compound libraries enriched in bioactivity have been reported. New con-
cepts, including the fusion of NP fragments to create new scaffolds or pseudo NPs,
are beginning to gain traction. These efforts will benefit greatly from increases in
technologies for automating the synthesis process. Automated systems that canChem 4, 705–730, April 12, 2018 725
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See Parker et al.85cater for a large array of reaction types will ensure that more time is made available
for assessing a compound’s bioactivity.
An additional area of debate in the field is how to select compounds to maximize
diversity in a compound library. In this respect, computational predictions of
chemical diversity are not necessarily predictive of biological diversity. However,
predicting biological diversity a priori still remains a major challenge. The introduc-
tion of the ‘‘cell-painting assay’’ has delivered a powerful tool for assessing a com-
pound’s biological profile, provided that it causes a change in cellular morphology
for the organelles stained. Diverse fingerprints in this assay can be used as a metric
for the construction of focused chemical libraries that cover a broad range of bio-
logical space. This is likely to be most useful for the design of libraries specifically
targeted to phenotypic screens. In this context, increasing complexity and similar-
ity to NPs were shown to be beneficial for increasing hit rates.101
Phenotypic screening is an area that is continuing to see great developments. New
assays that truly mimic a disease state are still challenging to achieve; however,
advances in the culture and use of induced pluripotent stem cells and organoids
are very promising steps in the right direction.102,103 Whole-organism screens in
zebrafish and Drosophila are also gaining in traction and will add to the repertoire
of options available for assessing a compound’s bioactivity. Recent advances in
whole-organism phenotypic screening in neurology have led to the development
of the SmartCube assay system, which monitors behavioral changes in mice
subjected to test compounds by using automated video acquisition and
analysis.104 After decades in which scientists sought to miniaturize assay systems
and move away from whole-animal screening, these screening formats are
beginning to increase in popularity and have seen significant technological
advances.
An area that remains challenging in phenotype-driven chemical biology is the iden-
tification of a hit’s target proteins. Although a range of different techniques for this
purpose have been described, the best results are often obtained through the simul-
taneous application of multiple strategies. This is because no single unifying strategy
that can successfully identify a range of target types exists. MS-based proteomic
strategies are successful for soluble proteins; however, membrane proteins are726 Chem 4, 705–730, April 12, 2018
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Adapted from Laraia and Waldmann.54traditionally difficult and are best identified with covalent probes that allow more
stringent washes in the subsequent purification stages. Hit prioritization remains a
significant challenge because all of the described techniques typically yield multiple
potential targets, which can be extremely challenging to (de)validate, depending on
target type. It is also important to note that nucleic acids and lipids can also be tar-
gets for small molecules, and methods of identifying and validating them are still in
their infancy. This also raises the question of which chemical matter is required for
targeting these entities and whether the current screening collections contain
such compounds or not in an academic and commercial setting.
In summary, despite the challenges outlined, new methods for the synthesis and
identification of biologically active small molecules continue to be developed.
Advances in synthesis, automation, cheminformatics, screening, bioinformatics,Chem 4, 705–730, April 12, 2018 727
and target identificationmean that the field will rise in importance and relevance and
will continue to see growth and success for years to come.
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